Iron Triangle Partners’s AstraZeneca AZN Stock Holding History

Iron Triangle Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-188,165	Closed	-$27.7M	–	29
2025 Q1	$27.7M	Buy	+188,165	New	+$27.2M	4.36%	9
2022 Q3	–	Sell	-218,739	Closed	-$28.9M	–	29
2022 Q2	$28.9M	Buy	218,739 +28,739	+15%	+$3.77M	3.75%	12
2022 Q1	$25.2M	Buy	+190,000	New	+$22.8M	3%	16
2021 Q4	–	Sell	-150,000	Closed	-$18M	–	26
2021 Q3	$18M	Buy	+150,000	New	+$17.5M	2.59%	18

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Iron Triangle Partners's AZN Position: Q2 2025 in Review

Iron Triangle Partners sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 188,165 shares — an estimated $27.7M sold.

Iron Triangle Partners first reported a position in AZN in Q3 2021 and held it in 4 quarters. The position peaked at $28.9M in Q2 2022. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Iron Triangle Partners reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Iron Triangle Partners sold 188,165 AstraZeneca shares in Q2 2025, an estimated $27.7M.
Iron Triangle Partners first reported a position in AstraZeneca in Q3 2021 and held it in 4 quarters.
Iron Triangle Partners's AstraZeneca position peaked at $28.9M in Q2 2022.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Iron Triangle Partners's 13F filing for Q2 2025, filed 14 Aug 2025.